Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2

Hideyuki Ikeda, Maiko Matsushita, Quinten Waisfisz, Akitoshi Kinoshita, Anneke B. Oostra, Aggie W M Nieuwint, Johan P. De Winter, Maureen Hoatlin, Yohko Kawai, Masao S. Sasaki, Alan D. D'Andrea, Yutaka Kawakami, Hans Joenje

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

A 2-year old boy was diagnosed with Fanconi anemia (FA) and acute myeloid leukemia (AML). A cell line (termed FA-AML1) was established from blast cells obtained after a second relapse after a successful bone marrow transplant. Histochemical and surface marker analysis confirmed that the cells were derived from the myeloid lineage. Cytogenetic analysis revealed multiple chromosomal aberrations, including a ring 7. Stable proliferation of the cultured cells was absolutely dependent on the presence of granulocyte macrophage colony-stimulating factor or interleukin 3. This is the first AML cell line successfully established from a FA patient. Remarkably, FA-AML1 cells appeared to lack the characteristic cellular FA phenotype, i.e., a hypersensitivity to growth inhibition and chromosomal breakage by the cross-linking agent mitomycin C. Genomic DNA from the patient showed biallelic mutations [8415G>T (K2729N)and 8732C>A (S2835STOP)] in the breast cancer susceptibility gene FANCD1/BRCA2 [N. Howlett et al., Science (Wash. DC), 297: 606-609, 2002]. In the AML cells, however, the 8732C>A nonsense mutation was changed into a missense mutation by a secondary alteration, 8731T>G, resulting in 2835E, which restored the open-reading frame of the gene and could explain the reverted phenotype of these cells. Loss of the FA phenotype by genetic correction of a FA gene mutation during AML progression may be a common late event in the pathogenesis of AML in FA patients, which may be treatment related. This finding suggests a novel mechanistic principle of tumor progression based on the genetic correction of an early caretaker gene defect.

Original languageEnglish (US)
Pages (from-to)2688-2694
Number of pages7
JournalCancer Research
Volume63
Issue number10
StatePublished - May 15 2003

Fingerprint

Fanconi Anemia
Acute Myeloid Leukemia
Cell Line
Mutation
Myeloid Cells
Phenotype
Genes
Chromosome Breakage
Nonsense Codon
Interleukin-3
Cytogenetic Analysis
Neoplasm Genes
Mitomycin
Missense Mutation
Granulocyte-Macrophage Colony-Stimulating Factor
Chromosome Aberrations
Open Reading Frames
Cultured Cells
Hypersensitivity
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ikeda, H., Matsushita, M., Waisfisz, Q., Kinoshita, A., Oostra, A. B., Nieuwint, A. W. M., ... Joenje, H. (2003). Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Research, 63(10), 2688-2694.

Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. / Ikeda, Hideyuki; Matsushita, Maiko; Waisfisz, Quinten; Kinoshita, Akitoshi; Oostra, Anneke B.; Nieuwint, Aggie W M; De Winter, Johan P.; Hoatlin, Maureen; Kawai, Yohko; Sasaki, Masao S.; D'Andrea, Alan D.; Kawakami, Yutaka; Joenje, Hans.

In: Cancer Research, Vol. 63, No. 10, 15.05.2003, p. 2688-2694.

Research output: Contribution to journalArticle

Ikeda, H, Matsushita, M, Waisfisz, Q, Kinoshita, A, Oostra, AB, Nieuwint, AWM, De Winter, JP, Hoatlin, M, Kawai, Y, Sasaki, MS, D'Andrea, AD, Kawakami, Y & Joenje, H 2003, 'Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2', Cancer Research, vol. 63, no. 10, pp. 2688-2694.
Ikeda H, Matsushita M, Waisfisz Q, Kinoshita A, Oostra AB, Nieuwint AWM et al. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Research. 2003 May 15;63(10):2688-2694.
Ikeda, Hideyuki ; Matsushita, Maiko ; Waisfisz, Quinten ; Kinoshita, Akitoshi ; Oostra, Anneke B. ; Nieuwint, Aggie W M ; De Winter, Johan P. ; Hoatlin, Maureen ; Kawai, Yohko ; Sasaki, Masao S. ; D'Andrea, Alan D. ; Kawakami, Yutaka ; Joenje, Hans. / Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. In: Cancer Research. 2003 ; Vol. 63, No. 10. pp. 2688-2694.
@article{d0bc0ff8ca5a41a9b33707c240bcf186,
title = "Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2",
abstract = "A 2-year old boy was diagnosed with Fanconi anemia (FA) and acute myeloid leukemia (AML). A cell line (termed FA-AML1) was established from blast cells obtained after a second relapse after a successful bone marrow transplant. Histochemical and surface marker analysis confirmed that the cells were derived from the myeloid lineage. Cytogenetic analysis revealed multiple chromosomal aberrations, including a ring 7. Stable proliferation of the cultured cells was absolutely dependent on the presence of granulocyte macrophage colony-stimulating factor or interleukin 3. This is the first AML cell line successfully established from a FA patient. Remarkably, FA-AML1 cells appeared to lack the characteristic cellular FA phenotype, i.e., a hypersensitivity to growth inhibition and chromosomal breakage by the cross-linking agent mitomycin C. Genomic DNA from the patient showed biallelic mutations [8415G>T (K2729N)and 8732C>A (S2835STOP)] in the breast cancer susceptibility gene FANCD1/BRCA2 [N. Howlett et al., Science (Wash. DC), 297: 606-609, 2002]. In the AML cells, however, the 8732C>A nonsense mutation was changed into a missense mutation by a secondary alteration, 8731T>G, resulting in 2835E, which restored the open-reading frame of the gene and could explain the reverted phenotype of these cells. Loss of the FA phenotype by genetic correction of a FA gene mutation during AML progression may be a common late event in the pathogenesis of AML in FA patients, which may be treatment related. This finding suggests a novel mechanistic principle of tumor progression based on the genetic correction of an early caretaker gene defect.",
author = "Hideyuki Ikeda and Maiko Matsushita and Quinten Waisfisz and Akitoshi Kinoshita and Oostra, {Anneke B.} and Nieuwint, {Aggie W M} and {De Winter}, {Johan P.} and Maureen Hoatlin and Yohko Kawai and Sasaki, {Masao S.} and D'Andrea, {Alan D.} and Yutaka Kawakami and Hans Joenje",
year = "2003",
month = "5",
day = "15",
language = "English (US)",
volume = "63",
pages = "2688--2694",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2

AU - Ikeda, Hideyuki

AU - Matsushita, Maiko

AU - Waisfisz, Quinten

AU - Kinoshita, Akitoshi

AU - Oostra, Anneke B.

AU - Nieuwint, Aggie W M

AU - De Winter, Johan P.

AU - Hoatlin, Maureen

AU - Kawai, Yohko

AU - Sasaki, Masao S.

AU - D'Andrea, Alan D.

AU - Kawakami, Yutaka

AU - Joenje, Hans

PY - 2003/5/15

Y1 - 2003/5/15

N2 - A 2-year old boy was diagnosed with Fanconi anemia (FA) and acute myeloid leukemia (AML). A cell line (termed FA-AML1) was established from blast cells obtained after a second relapse after a successful bone marrow transplant. Histochemical and surface marker analysis confirmed that the cells were derived from the myeloid lineage. Cytogenetic analysis revealed multiple chromosomal aberrations, including a ring 7. Stable proliferation of the cultured cells was absolutely dependent on the presence of granulocyte macrophage colony-stimulating factor or interleukin 3. This is the first AML cell line successfully established from a FA patient. Remarkably, FA-AML1 cells appeared to lack the characteristic cellular FA phenotype, i.e., a hypersensitivity to growth inhibition and chromosomal breakage by the cross-linking agent mitomycin C. Genomic DNA from the patient showed biallelic mutations [8415G>T (K2729N)and 8732C>A (S2835STOP)] in the breast cancer susceptibility gene FANCD1/BRCA2 [N. Howlett et al., Science (Wash. DC), 297: 606-609, 2002]. In the AML cells, however, the 8732C>A nonsense mutation was changed into a missense mutation by a secondary alteration, 8731T>G, resulting in 2835E, which restored the open-reading frame of the gene and could explain the reverted phenotype of these cells. Loss of the FA phenotype by genetic correction of a FA gene mutation during AML progression may be a common late event in the pathogenesis of AML in FA patients, which may be treatment related. This finding suggests a novel mechanistic principle of tumor progression based on the genetic correction of an early caretaker gene defect.

AB - A 2-year old boy was diagnosed with Fanconi anemia (FA) and acute myeloid leukemia (AML). A cell line (termed FA-AML1) was established from blast cells obtained after a second relapse after a successful bone marrow transplant. Histochemical and surface marker analysis confirmed that the cells were derived from the myeloid lineage. Cytogenetic analysis revealed multiple chromosomal aberrations, including a ring 7. Stable proliferation of the cultured cells was absolutely dependent on the presence of granulocyte macrophage colony-stimulating factor or interleukin 3. This is the first AML cell line successfully established from a FA patient. Remarkably, FA-AML1 cells appeared to lack the characteristic cellular FA phenotype, i.e., a hypersensitivity to growth inhibition and chromosomal breakage by the cross-linking agent mitomycin C. Genomic DNA from the patient showed biallelic mutations [8415G>T (K2729N)and 8732C>A (S2835STOP)] in the breast cancer susceptibility gene FANCD1/BRCA2 [N. Howlett et al., Science (Wash. DC), 297: 606-609, 2002]. In the AML cells, however, the 8732C>A nonsense mutation was changed into a missense mutation by a secondary alteration, 8731T>G, resulting in 2835E, which restored the open-reading frame of the gene and could explain the reverted phenotype of these cells. Loss of the FA phenotype by genetic correction of a FA gene mutation during AML progression may be a common late event in the pathogenesis of AML in FA patients, which may be treatment related. This finding suggests a novel mechanistic principle of tumor progression based on the genetic correction of an early caretaker gene defect.

UR - http://www.scopus.com/inward/record.url?scp=0037842201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037842201&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 2688

EP - 2694

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -